Loading
No description yet: the sentence for this tag has not been written. 10 records carry it: 10 drugs.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
ARX517 JNJ-95298177 ARX517 is an experimental antibody-drug conjugate for metastatic prostate cancer, aimed at the protein PSMA. Ambrx developed it and Johnson & Johnson took it over when it bought Ambrx in 2024. | Phase 1 | Prostate cancer | none | pipeline | |
AVZO-1418 DB-1418 AVZO-1418 is an experimental antibody-drug conjugate that targets two proteins, EGFR and HER3, on cancer cells. Avenzo Therapeutics licensed it from DualityBio and is testing it in a first phase 1/2 trial in advanced solid tumours. | Phase 2 | Non-small-cell lung cancer, Biliary tract cancer, Bladder & urothelial cancer | none | pipeline | |
IBI3009 IBI3009 is an experimental antibody-drug conjugate for small cell lung cancer, aimed at the protein DLL3. Innovent Biologics licensed it to Roche in January 2025, and it is in a first phase 1 trial. | Phase 1 | Small-cell lung cancer | none | pipeline | |
LB2102 LB2102 is an experimental CAR-T cell therapy for small cell lung cancer, made from a patient's own immune cells and aimed at the protein DLL3. Legend Biotech licensed it to Novartis in November 2023. | Phase 1 | Small-cell lung cancer | none | pipeline | |
LM-299 MK-2010 LM-299 is an experimental antibody that blocks two things at once: PD-1, a brake on the immune system, and VEGF, which feeds tumour blood vessels. LaNova Medicines discovered it and Merck licensed it in 2024, where it is called MK-2010. | Phase 2 | none | none | pipeline | |
Lutetium Lu 177 dotatate (PNT2003) PNT2003 PNT2003 is a generic version of Lutathera, the radioactive treatment for neuroendocrine tumours of the gut and pancreas. Lantheus licensed it from POINT Biopharma and received tentative FDA approval in March 2026; full approval was waiting on a patent dispute. | Emerging | Neuroendocrine tumours | none | pipeline | |
SHR-4849 IDE849 SHR-4849, called IDE849 by IDEAYA Biosciences, is an experimental antibody-drug conjugate aimed at the protein DLL3 in small cell lung cancer and neuroendocrine tumours. Hengrui discovered it and licensed rights outside Greater China to IDEAYA in December 2024. | Phase 2 | Small-cell lung cancer | none | pipeline | |
SHR-A1904 SHR-A1904 is Hengrui's experimental antibody-drug conjugate aimed at Claudin 18.2, in a phase 3 trial against standard second-line treatment for advanced stomach cancer. Merck KGaA holds an option to license it outside China. | Phase 3 | Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Biliary tract cancer | none | pipeline | |
Tulmimetostat DZR123 Tulmimetostat is an experimental tablet that blocks the gene-silencing enzymes EZH1 and EZH2. Novartis gained it by buying MorphoSys in 2024 and is testing it in prostate cancer, lymphomas and other solid tumours. | Phase 2 | Prostate cancer, Metastatic castration-resistant prostate cancer, Diffuse large B-cell lymphoma | none | pipeline | |
YL211 YL211 is an experimental antibody-drug conjugate aimed at c-MET, a protein on some solid tumours. MediLink Therapeutics licensed worldwide rights to Roche in January 2024, and it is in a first phase 1 trial. | Phase 1 | Non-small-cell lung cancer | none | pipeline |